看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: K- F! Y U0 k4 u
8 W6 x' E* |6 {; E2 c' I: R* r
) I+ I% Z% Q# {$ X4 g3 S3 J6 KCurrently available feasibility data for possible combination strategies. - S, k. T7 v9 w. o$ e4 b( z
————————————————————————————————
' | v! T7 u& CCombination Feasibility according to preliminary data 7 X, i/ p0 Z' A X
——————————————————————————————————
8 h9 ] Q% d! A: e sBevacizumab + sorafenib Yes, reduced dose
2 O: `8 b9 G% m& h5 O9 M' ?$ yBevacizumab + sunitinib† No ; M w8 b0 H2 l, t' ]
Bevacizumab + temsirolimus Yes 8 |7 [. Z# w% P2 w
Bevacizumab + everolimus Yes / D& c3 P* A6 o8 l$ y" x4 ~
Sorafenib + sunitinib ? : a) @0 s: M& p ^9 M6 @1 l
Sorafenib + temsirolimus Yes, reduced dose 0 U1 [- P6 h: S9 R- v
Sorafenib + everolimus Yes, reduced dose
- F! N% I4 ^: g' Y7 P2 XSunitinib + temsirolimus† No 2 D- E! _5 X, R, ^0 { C
Sunitinib + everolimus ?
; H) T1 d1 s: m: xTemsirolimus + everolimus ? - t1 d, ?4 w, H9 D
————————————————————9 T9 d7 S2 h' k3 o- b; [
†Led to US FDA warning.. ~3 O! ?1 B/ n# P) O* x/ H
?: As yet unattempted combination.
: d( U' u- z \/ _% L |
显身卡
